WallStSmart

Eli Lilly and Company (LLY)vsSight Sciences Inc (SGHT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 97713% more annual revenue ($86.46B vs $88.39M). LLY leads profitability with a 31.9% profit margin vs -32.1%. LLY earns a higher WallStSmart Score of 74/100 (B).

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

SGHT

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: -3.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

SGHTUndervalued (+33.3%)

Margin of Safety

+33.3%

Fair Value

$8.29

Current Price

$10.59

$2.30 discount

UndervaluedFair: $8.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

SGHT1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

Areas to Watch

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

SGHT4 concerns · Avg: 3.3/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$601.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-57.8%2/10

ROE of -57.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bull Case : SGHT

The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Bear Case : SGHT

The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

SGHT carries more volatility with a beta of 2.40 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (74/100 vs 27/100), backed by strong 31.9% margins and 38.6% revenue growth. SGHT offers better value entry with a 33.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Sight Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.

Want to dig deeper into these stocks?